MedPath

The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia

Not Applicable
Completed
Conditions
Androgenic Alopecia
Registration Number
NCT02594046
Lead Sponsor
Pusan National University Hospital
Brief Summary

This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of the allogeneic human adipose derived stem cell component extract on androgenic alopecia in relatively healthy adults. A total of 38 subjects received 1.2 g of allogeneic human adipose derived stem cell component extract per month or a placebo for 16 weeks.

Detailed Description

This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of the allogeneic human adipose derived stem cell component extract on androgenic alopecia in relatively healthy adults. A total of 38 subjects received 1.2 g of allogeneic human adipose derived stem cell component extract per month or a placebo for 16 weeks. Hair count and thickness will be primary outcomes.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
38
Inclusion Criteria
  • androgenic alopecia basic and specific(BASP) classification: M2, C2, U1, V1, or F1 or higher
Exclusion Criteria
  • patient of scalp disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
change of total hair counts by phototrichogram16 weeks
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.